Recent anti-CTLA-4 (ipilimumab) linked to IL-6–high immunosuppressive profile and ~6× shorter OS on PD-L1 + CD40/4-1BB adenoviral gene therapy in PD-1–refractory melanoma

LOKON003 combines an anti–PD-L1 antibody with a replication-competent adenoviral immunogene therapy designed to stimulate CD40 and 4-1BB signaling (NCT04123470) in anti–PD-1–refractory metastatic melanoma (Phase I/II; n=24 enrolled; baseline clustering reported for n=23). At baseline, an “hyperactive immunosuppressive” plasma protein signature (n=8) tracked with markedly worse survival: median OS 4.0 months vs 28.1 months without the signature (n=15); independently, recent anti-CTLA-4 exposure within 12 months (n=10) also separated outcomes (mOS 5.3 vs 30.7 months for later/none, n=14) and was associated with an IL-6–centered upregulated network. Safety and response rates were not reported in this abstract, and the OS deltas are hypothesis-generating in a very small, biomarker-defined subset—still notable because salvage outcomes after PD-1 failure are commonly poor, with retrospective ipilimumab-after–anti–PD-1 series reporting mOS ~5 months.